sponsored
PatientsVille.com Logo

PatientsVille

Dayquil Medical Research Studies

Up-to-date List of Dayquil Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Dayquil Medical Research Studies

Rank Status Study
1 Recruiting A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
Conditions: Nocturia;   Daytime Sleepiness
Intervention: Drug: Armodafinil 50 - 250 mg pills
Outcome Measures: Change in Epworth Sleepiness Scale;   Clinical Global Impressions, change in severity of excessive daytime sleepiness (EDS);   Number of naps;   Number of minutes napped based on sleep diary
2 Recruiting SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
Condition: Chronic Fatigue Syndrome
Interventions: Drug: Sodium Oxybate;   Other: placebo (fresh potable water)
Outcome Measures: EEG slow wave activity during sleep;   Daytime sleepiness
3 Recruiting Effects of Brain Stimulation During Daytime Nap on Memory Consolidation in Younger, Healthy Subjects
Condition: Healthy Subjects
Interventions: Device: brain stimulation;   Device: no stimulation
Outcome Measures: Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS;   Amount of Slow wave Sleep;   2. sleep spindles;   3. EEG-correlates;   4. further memory systems
4 Recruiting Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Patients With Mild Cognitive Impairment
Condition: Mild Cognitive Impairment, So Stated
Interventions: Device: SHAM stimulation;   Device: 0,75 Hz stimulation
Outcome Measures: Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS;   Amount of Slow wave Sleep, spindels, eeg-correlates, further memory systems
5 Recruiting Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
Conditions: Narcolepsy With Cataplexy;   Excessive Daytime Sleepiness
Interventions: Drug: Pitolisant;   Drug: Placebo
Outcome Measures: Measure of anticataplectic efficacy;   Excessive Daytime Sleepiness assessment;   Safety assessment
6 Recruiting Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention: Device: Non-invasive home ventilation
Outcome Measures: Difference in the number of respiratory therapist interventions required using IVAPS vs BIST mode of ventilation in patients with ALS.;   Feasibility of initiating long term home ventilation in ALS patients using the Stellar 150 iVAPS mode during a single daytime trial.;   Difference in symptoms with IVAPS vs. BiST in ALS patients;   Effectiveness of ventilation by IVAPS vs. BiST on night-time respiratory parameters in ALS patients;   Long-term compliance with the use of nocturnal ventilation on IVAPS vs. BiST in ALS patients
7 Recruiting ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.
Conditions: Heart Failure;   Obstructive Sleep Apnea;   Central Sleep Apnea
Intervention: Other: [C11]Acetate and HED PET
Outcome Measures: ASV therapy yields a reduction in the rate of oxidative metabolism as measured by [11C]acetate kinetics using PET imaging in patients with HF, OSA and/or CSA;   ASV therapy yields an improvement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index inpatients with HF, OSA and/or CSA.;   ASV for CSA or OSA in patients with HF and sleep apnea will normalize daytime myocardial SN pre-synaptic function measured by [11C]HED retention on PET imaging,;   ASV for CSA or OSA in patients with HF and sleep apnea will normalize daytime sympathetic contributions to heart rate variability
8 Unknown  Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation
Outcome Measures: To evaluate endothelial dysfunction (as measured by Peripheral arterial tone (PAT)) and its evolution after four weeks withdrawal of non-invasive ventilation (NIV).;   To assess arterial stiffness, systemic inflammation (IL6, TNFα, Leptin, CRP), insulin resistance, DHEA, sleep quality, objective and subjective daytime somnolence and their evolution after four weeks withdrawal of NIV.
9 Recruiting Non-invasive Haemodynamic Assessment in Hypertension
Condition: Arterial Hypertension
Interventions: Drug: lisinopril;   Drug: Telmisartan;   Drug: Nebivolol;   Drug: Indapamide/hydrochlorothiazide;   Drug: Amlodipine
Outcome Measures: 24-h mean Systolic Blood Pressure (in ABPM);   24-h mean Diastolic Blood Pressure (in ABPM);   daytime mean Systolic Blood Pressure (in ABPM);   daytime mean Diastolic Blood Pressure (in ABPM);   night-time mean Systolic Blood Pressure (in ABPM);   night-time mean Diastolic Blood Pressure (in ABPM);   Systolic Blood Pressure (in OBPM);   Diastolic Blood Pressure (in OBPM);   change from baseline in Systolic Blood Pressure (in OBPM) at 3 months;   change from baseline in Diastolic Blood Pressure (in OBPM) at 3 months;   change from baseline in 24-h Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in 24-h Diastolic Blood Pressure (in ABPM) at 3 months;   change from baseline in daytime Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in daytime Diastolic Blood Pressure (in ABPM) at 3 months;   change from baseline in night-time Systolic Blood Pressure (in ABPM) at 3 months;   change from baseline in night-time Diastolic Blood Pressure (in ABPM) at 3 months
10 Recruiting Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults
Condition: Older Adults (50-80 Years)
Interventions: Device: brain stimulation;   Device: Sham Stimulation
Outcome Measures: Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS;   1. Amount of Slow wave Sleep;   2. sleep spindels;   3. EEG-correlates;   4. further memory systems
11 Unknown  Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness
Condition: Sleep Apnea
Intervention:
Outcome Measure:
12 Unknown  Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
Condition: COPD
Interventions: Drug: fluticasone/salmeterol 250/50;   Drug: placebo
Outcome Measures: The aim of this study is to determine the effect of fluticasone/salmeterol on sleep quality in patients with COPD and to compare efficacy of Advair 250 compared to placebo on sleep.;   daytime somnolence
13 Recruiting Gene Expression in the Overactive Bladder in Children
Conditions: Overactive Bladder;   Children
Intervention:
Outcome Measure: Up- and down regulation of genes expressed in the bladder
14 Recruiting Determining How Quickly Progesterone Slows LH Pulse Frequency
Condition: PCOS
Interventions: Drug: oral micronized P suspension;   Other: Placebo
Outcome Measures: The primary endpoint is the change in the number of LH pulses (over 10 h) attributable to Progesterone.;   acute effects of P on mean LH;   acute effects of P on mean LH pulse amplitude;   acute effects of P on mean FSH
15 Recruiting Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
Condition: Sleep-wake Disturbances in Motor-phase Parkinson`s Disease
Intervention: Drug: Sodium Oxybate
Outcome Measures: Objective excessive daytime sleepiness;   effect on night-time breathing;   Motor function;   Subjective quality of nocturnal sleep;   Objective quality of nocturnal sleep including breathing indices;   Quality of life;   Mood;   Cognition;   Impulse control;   Vigilance;   Subjective Daytime sleepiness;   Sleep wake rhythm;   Quality of life for caregivers
16 Recruiting Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Condition: Menopause
Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia;   Behavioral: Sleep Education;   Behavioral: Sleep Restriction Therapy
Outcome Measures: Sleep;   Depression;   Quality of life
17 Recruiting Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone
Conditions: Polycystic Ovary Syndrome;   Hyperandrogenism
Interventions: Drug: Progesterone;   Drug: Placebo
Outcome Measures: Average luteinizing hormone (LH) interpulse interval and the total number of LH pulses;   Hourly hormone measurements during sampling period.
18 Recruiting Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
Condition: Prehypertension
Interventions: Dietary Supplement: Marealis refined peptide concentrate;   Dietary Supplement: Placebo
Outcome Measures: Change in daytime ambulatory systolic blood pressure from baseline;   Change in office systolic blood pressure from baseline;   Change in 24-hour and nighttime ambulatory systolic blood pressure from baseline;   Change in 24-hour, daytime and nighttime ambulatory diastolic blood pressure from baseline;   Changes in 24-hour, daytime and nighttime ambulatory systolic and ambulatory diastolic blood pressure from baseline;   Mean ambulatory systolic blood pressure (24-hour, daytime and nighttime);   Mean ambulatory diastolic blood pressure (24-hour, daytime and nighttime);   Change in office diastolic blood pressure from baseline;   Changes in office systolic and office diastolic blood pressure from baseline;   Mean Office systolic blood pressure;   Mean Office diastolic blood pressure
19 Recruiting Treatment Strategies for Children With Smith-Magenis Syndrome
Conditions: Developmental Delay Disorders;   Chromosome Deletion;   Mental Retardation;   Sleep Disorders, Circadian Rhythm;   Self Injurious Behavior
Interventions: Drug: dTR Melatonin (NIH CC PDS);   Device: Phototherapy (Bright Light);   Drug: Melatonin CR
Outcome Measures: Change in level of melatonin (pg/ml) from baseline;   Improved sleep parameters (actigraphy). Increased daytime vigilance. Decreased maladaptive behaviors.
20 Recruiting The Electronic Asthma Action Plan System for Implementation in Primary Care
Condition: Asthma
Intervention: Other: Electronic Asthma Action Plan System
Outcome Measures: The primary outcome will be the proportion of eligible patients to whom an AAP was delivered by the physician during the intervention period (52 weeks) compared to the baseline period (52 weeks).;   The impact of the eAAPS on patient-relevant outcomes including hospitalisations, ER visits, unscheduled & total visits to the doctor, days off work/school, nocturnal & daytime asthma symptoms, daytime rescue bronchodilator use, & quality of life;   Proportion of all eligible patients who had asthma control documented;   Proportion of eligible patients who had a medication change made;   Proportion of eligible patients who had an appropriate medication change made (based on overall asthma control, when ascertainable);   Proportion of eligible patients to whom an AAP was delivered by the physician during the intervention period, when decision support was available (52 weeks), compared to the baseline period (52 weeks).

These studies may lead to new treatments and are adding insight into Dayquil etiology and treatment.

A major focus of Dayquil research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Dayquil